Sign inJoin waitlistJoin the waitlist

Poornima Saha

Clinical Associate Professor, The University of Chicago Pritzker School of Medicine · University of Chicago Medical Center

Credentials: · · · · ·

History

University of Chicago Medical Center
Present
University of Chicago Medical Center
Present

Hematology and Medical Oncology
University of Chicago Medical Center
2014–2017
Internal Medicine
University of Chicago Medical Center
2011–2014
Loyola University Chicago Stritch School of Medicine
2007–2011

Research

Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials
Journal of Clinical Oncology · 2017 · First of 28 authors · 127 citations
A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer
SpringerPlus · 2016 · 35 citations
LyP-1-Modified Oncolytic Adenoviruses Targeting Transforming Growth Factor β Inhibit Tumor Growth and Metastases and Augment Immune Checkpoint Inhibitor Therapy in Breast Cancer…
Human Gene Therapy · 2020 · 24 citations

Rita Nanda
7 papers
Frederick Howard
6 papers
Megan Sullivan
5 papers
Olufunmilayo Olopade
5 papers
Alexander Pearson
4 papers
EF
Elbio Flores
4 papers
Gini Fleming
4 papers
Katharine Yao
4 papers
Nan Chen
4 papers
Suzanne Conzen
4 papers
Erica Stringer-Reasor
3 papers
Allison DePersia
2 papers

Clinical trials

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2033
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Site PI · Recruiting · Phase 3
NRG Oncology
2023–2034
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Site PI · Recruiting · Phase 3
SWOG Cancer Research Network
2023–2033
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2023–2033